Evaluation of the efficacy of esomeprazole in suppressing nausea and vomiting in patients undergoing chemotherapy for breast cancer.

Trial Profile

Evaluation of the efficacy of esomeprazole in suppressing nausea and vomiting in patients undergoing chemotherapy for breast cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 May 2012

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Acronyms NEXIUM
  • Most Recent Events

    • 06 Mar 2012 Actual patient number changed from 46 to 43 as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top